Curated News
By: NewsRamp Editorial Staff
March 05, 2026

HeartBeam Enrolls First Patients in Groundbreaking Heart Attack Detection Study

Discuss on LinkedIn Discuss on Substack
Original Source

TLDR

  • HeartBeam's ALIGN-ACS pilot study positions the company to expand its FDA-cleared 3D ECG technology from arrhythmia to heart attack detection, creating a competitive edge in cardiac diagnostics.
  • The HeartBeam System collects ECG signals in 3D from non-coplanar directions and synthesizes them into a 12-lead ECG for portable heart attack detection outside medical facilities.
  • HeartBeam's technology enables earlier heart attack detection through portable devices, potentially saving lives by allowing timely intervention and improving cardiac care accessibility worldwide.
  • HeartBeam's cable-free 3D ECG device, already FDA-cleared for arrhythmia, now enters a pilot study to detect heart attacks using innovative signal synthesis technology.

Impact - Why it Matters

This development represents a potential paradigm shift in cardiac care that could save lives by enabling earlier heart attack detection outside hospital settings. Heart attacks remain a leading cause of death worldwide, with delayed diagnosis contributing significantly to poor outcomes. Current ECG technology typically requires hospital visits and specialized equipment, creating barriers to timely intervention. HeartBeam's portable 3D ECG system could democratize access to sophisticated cardiac monitoring, allowing for earlier detection during critical moments when every minute counts. For patients with cardiac risk factors, this technology could provide peace of mind through continuous monitoring, while for healthcare systems, it could reduce emergency room visits and hospitalizations through better preventive care. The successful expansion of this technology from arrhythmia to heart attack detection could fundamentally change how we approach cardiac emergencies, moving from reactive treatment in hospitals to proactive monitoring in daily life.

Summary

HeartBeam Inc., a pioneering medical technology company trading on NASDAQ as BEAT, has achieved a significant milestone in cardiac care innovation with the enrollment of the first patients in its groundbreaking ALIGN-ACS pilot study. This clinical trial, led by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, marks a crucial step toward expanding the HeartBeam System's capabilities beyond its current FDA-cleared use for arrhythmia assessment to include heart attack detection. The study represents a key advancement in generating the clinical data needed to potentially transform how acute cardiac events are identified and managed outside traditional medical facilities.

At the core of this development is HeartBeam's revolutionary technology platform, which creates the first-ever cable-free device capable of collecting electrocardiogram (ECG) signals in three-dimensional space from three non-coplanar directions. This innovative approach synthesizes these signals into a comprehensive 12-lead ECG, providing physicians with powerful cardiac insights that were previously only available in clinical settings. The company's technology has already received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025, supported by over 20 issued patents that protect this transformative approach to cardiac monitoring.

The potential impact of this technology extends far beyond the clinical trial setting, promising to redefine cardiac health management by enabling portable, actionable heart intelligence wherever patients may be. By allowing physicians to identify cardiac health trends and acute conditions outside medical facilities, HeartBeam's system could dramatically improve early detection of heart attacks and other critical cardiac events. For those interested in following this developing story, the latest news and updates relating to BEAT are available in the company's newsroom, while the full press release can be accessed for complete details about this promising advancement in cardiac care technology.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, HeartBeam Enrolls First Patients in Groundbreaking Heart Attack Detection Study

blockchain registration record for this content.